Search

New results from a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK), gastrointestinal oncologists Andrea Cercek, MD, and Luis Diaz Jr., MD, demonstrates how immunotherapy alone can allow people with MMRd cancers to avoid surgery and preserve their quality of life.

… Sunday, April 27, 2025 CHICAGO —   New results from a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK), gastrointestinal oncologists  Andrea Cercek, MD , and  Luis Diaz Jr., MD, demonstrate how immunotherapy alone can allow people with  MMRd cancers to avoid surgery and preserve their

Women want to understand and decrease their risk of breast cancer, and Nicole Saphier, MD, Director of Breast Imaging at MSK Monmouth, wants to ensure that women make the right decisions when it comes to their breast health this October, in honor of Breast Cancer Awareness Month, and every day.

… Tuesday, October 23, 2018 Women want to understand and decrease their risk of  breast cancer ,  and Nicole Saphier, MD , Director of Breast Imaging at  MSK Monmouth , wants to ensure that women make the right decisions when it comes to their breast health this October, in honor of Breast Cancer Awareness

Total neoadjuvant therapy is a viable treatment strategy for patients with locally advanced rectal cancer and is associated with the potential to sidestep surgical treatment.

… Monday, September 10, 2018 Total neoadjuvant therapy is a viable treatment strategy for patients with locally advanced rectal cancer and is associated with improved delivery of planned therapy, increased downstaging, earlier introduction of optimal systemic chemotherapy to address micrometastases, and

Physician-scientist Michael S. Glickman specializes in the treatment and study of infectious diseases.

… Wednesday, October 1, 2008 Summary Physician-scientist Michael S. Glickman specializes in the treatment and study of infectious diseases. Physician-scientist Michael S. Glickman specializes in the treatment and study of infectious diseases. In the clinic he cares for cancer patients with a wide variety

MSK-ACCESS, a blood test that can detect mutations in 129 genes related to cancer, has already helped guide the treatment of more than 2,800 patients at MSK.

… Thursday, July 1, 2021 One of the most exciting recent developments in cancer care has been the increased use of liquid biopsies to analyze tumors. These tests, which are noninvasive and only require blood for testing, enable doctors to determine the genetic mutations driving the growth of a patient’

Tumor genomics and clinicopathologic features better predict recurrent lung adenocarcinoma (LUAD) following primary resection compared with the TNM classification system, according to a recent study from MSK.

… Monday, July 11, 2022 Tumor genomics and clinicopathologic features better predict recurrent lung adenocarcinoma (LUAD) following primary resection compared with the TNM classification system, according to a recent study from Memorial Sloan Kettering Cancer Center (MSK) published in JAMA Surgery .  (

Research led by investigators at Memorial Sloan Kettering Cancer Center has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice.

… Sunday, March 23, 2008 Research led by investigators at Memorial Sloan Kettering Cancer Center (MSKCC) has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson’s disease in mice. The study’s results are published in the March 23 online edition

Dr. Offodile will serve as MSK’s “futurist,” leading strategy efforts and care transformation initiatives at MSK by continuing to develop the core infrastructure, management systems, and processes for enterprise strategy and business development.

… Monday, April 24, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced that Anaeze Offodile II, MD, MPH , will join the institution as Chief Strategy Officer (CSO) on May 1. Dr. Offodile — a double board-certified physician with clinical expertise in oncologic reconstruction, a health services

Rather than promoting genetic chaos, loss of p53 leads to an orderly progression of genetic changes that no one saw coming.

… Wednesday, August 17, 2022 More than half of all cancers have mutations in a gene called p53 . The protein made from this gene is what’s called a tumor suppressor: When working properly, it guards against cancer development — in part, by detecting damaged DNA and alerting cells to repair it. Cells without

Recent advances in technology allow Memorial Sloan Kettering Cancer Center pathologists to perform swift and accurate molecular analyses of tumor cells in patients with colorectal cancer. By determining the gene mutations of individual tumors, doctors are able to prescribe treatments that are most likely to be effective for patients, while avoiding drugs that will provide no benefit and may cause serious side effects.

… Friday, October 1, 2010 Recent advances in technology allow Memorial Sloan Kettering Cancer Center pathologists to perform swift and accurate molecular analyses of tumor cells in patients with colorectal cancer. By determining the gene mutations of individual tumors, doctors may be able to prescribe